I will discuss our experimental and computational efforts on using CRISPR screens to identify novel therapy to treat hormone-independent breast cancer. I will also present our computational work on inference of tumor-infiltrating lymphocytes and T-cell receptor repertoire from TCGA RNA-seq Data.
Brief biographical information:
X. Shirley Liu received PhD in Biomedical Informatics and PhD minor in Computer Science from Stanford University in 2002. She is now Professor of Biostatistics and Computational Biology at Harvard T.H. Chan School of Public Health and the Director of the Center of Functional Cancer Epigenetics at Dana-Farber Cancer Institute. Her research focuses on algorithm development and integrative modelling of high throughput genomic data to understand the specificity and function of gene expression regulators in tumour development, progression, drug response and resistance. In computational biology, her laboratory developed widely used algorithms for transcription factor motif finding, ChIP-chip/seq, DNase-seq, and CRISPR screen data analysis. In epigenetics, she and colleagues identified the chromatin signature of embryonic pluripotency, and were the pioneers to use the dynamics of nucleosomes, histone marks, and DNase hypersensitivity to predict driving transcription factors and cis-elements in a biological process. In cancer biology, she and colleagues identified novel functions of ESR1, AR, FOXA1, EZH2, and NOTCH1 in various cancers, discovered many cancer-related long non-coding RNAs, and reported novel associations of tumour immunity with patient clinical features and outcome. Dr. Liu has an H-index of 62 according to Google Scholar statistics and has published over papers in 40 in Nature, Science or Cell series journals. She received the Sloan Research Fellowship in 2008, was named a Yangtze River Scholar and 1000 Talent Scholar in China in 2012 and 2013, and was selected to receive the Richard E. Weitzman Outstanding Early Career Investigator Award from the Endocinoe Society in 2016.